United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Alliancebernstein L.P.

Alliancebernstein L.P. increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 28.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 709,043 shares of the biotechnology company’s stock after acquiring an additional 157,363 shares during the period. Alliancebernstein L.P. owned about 1.59% of United Therapeutics worth $250,179,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of UTHR. Townsquare Capital LLC acquired a new position in shares of United Therapeutics in the third quarter valued at approximately $426,000. CreativeOne Wealth LLC purchased a new stake in shares of United Therapeutics during the third quarter worth $215,000. Captrust Financial Advisors raised its stake in shares of United Therapeutics by 3.7% in the third quarter. Captrust Financial Advisors now owns 3,452 shares of the biotechnology company’s stock valued at $1,237,000 after acquiring an additional 124 shares in the last quarter. Edgestream Partners L.P. purchased a new position in United Therapeutics in the third quarter valued at $1,584,000. Finally, Erste Asset Management GmbH purchased a new stake in United Therapeutics during the 3rd quarter worth about $16,224,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $940,373.07. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of the company’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares of the company’s stock, valued at $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,500 shares of company stock valued at $26,134,500. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Price Performance

Shares of UTHR opened at $308.27 on Tuesday. United Therapeutics Co. has a 1-year low of $221.53 and a 1-year high of $417.82. The stock has a market cap of $13.85 billion, a PE ratio of 13.54, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. The firm has a fifty day moving average price of $339.04 and a 200 day moving average price of $355.62.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the business earned $4.36 EPS. As a group, equities analysts expect that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on UTHR shares. HC Wainwright reiterated a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.